The University of Chicago Header Logo

Connection

George Bakris to United States

Back to Details
This is a "connection" page, showing publications George Bakris has written about United States.
George Bakris
Connection Strength
2.237
United States
  1. Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023 08; 25(8):737-747.
    View in: PubMed
    Score: 0.096
  2. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 11; 102(5):974-989.
    View in: PubMed
    Score: 0.091
  3. ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. J Am Coll Cardiol. 2019 06 18; 73(23):3018-3026.
    View in: PubMed
    Score: 0.073
  4. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018 02 08; 378(6):497-499.
    View in: PubMed
    Score: 0.066
  5. Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease. Clin Pharmacol Ther. 2017 Sep; 102(3):450-458.
    View in: PubMed
    Score: 0.064
  6. Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. Circ J. 2017 Aug 25; 81(9):1337-1345.
    View in: PubMed
    Score: 0.063
  7. Update on blood pressure goals in diabetes mellitus. Curr Cardiol Rep. 2015 Jun; 17(6):37.
    View in: PubMed
    Score: 0.055
  8. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57.
    View in: PubMed
    Score: 0.052
  9. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. Am J Med. 2014 Jan; 127(1):S1.
    View in: PubMed
    Score: 0.049
  10. American Society of Hypertension, Inc: Leadership message. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):533.
    View in: PubMed
    Score: 0.041
  11. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011 Feb; 13(2):81-8.
    View in: PubMed
    Score: 0.041
  12. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens. 2010 Nov-Dec; 4(6):302-10.
    View in: PubMed
    Score: 0.040
  13. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int. 2010 Oct; 78(8):726-36.
    View in: PubMed
    Score: 0.039
  14. Leadership message. Forging ahead into the new healthcare frontier. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):631-2.
    View in: PubMed
    Score: 0.039
  15. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2009: executive summary. Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S1-3.
    View in: PubMed
    Score: 0.038
  16. Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S4-S14.
    View in: PubMed
    Score: 0.038
  17. The kidney, hypertension, and remaining challenges. Med Clin North Am. 2009 May; 93(3):697-715, Table of Contents.
    View in: PubMed
    Score: 0.036
  18. Executive summary: Kidney Early Evaluation Program (KEEP) 2008 annual data report. Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S1-2.
    View in: PubMed
    Score: 0.036
  19. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S22-31.
    View in: PubMed
    Score: 0.036
  20. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S3-10.
    View in: PubMed
    Score: 0.036
  21. Hypertension and kidney disease: a combination that should be prevented. Nephrol News Issues. 2009 Feb; 23(2):42, 44, 46.
    View in: PubMed
    Score: 0.035
  22. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008 Nov 25; 52(22):1749-57.
    View in: PubMed
    Score: 0.035
  23. ASH: renaissance of a society -- a movement of vigorous renewal. J Clin Hypertens (Greenwich). 2008 Oct; 10(10):808.
    View in: PubMed
    Score: 0.035
  24. KEEP launches follow-up initiative aimed at predicting the future. Nephrol News Issues. 2008 Sep; 22(10):44-6.
    View in: PubMed
    Score: 0.034
  25. CKD awareness in the United States: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Aug; 52(2):382-3.
    View in: PubMed
    Score: 0.034
  26. New onset diabetes: can it be delayed? J Hum Hypertens. 2008 Aug; 22(8):517-9.
    View in: PubMed
    Score: 0.034
  27. Executive summary: Kidney Early Evaluation Program (KEEP) 2007 Annual Data Report. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S1-2.
    View in: PubMed
    Score: 0.033
  28. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S30-7.
    View in: PubMed
    Score: 0.033
  29. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):130-9.
    View in: PubMed
    Score: 0.033
  30. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr. 2008; 3(4):229-33.
    View in: PubMed
    Score: 0.033
  31. Pharmacological augmentation of endothelium-derived nitric oxide synthesis. J Manag Care Pharm. 2007 Jun; 13(5 Suppl):S9-12.
    View in: PubMed
    Score: 0.031
  32. Case study: the link between hypertension and diabetes. J Manag Care Pharm. 2007 Jun; 13(5 Suppl):S17-9.
    View in: PubMed
    Score: 0.031
  33. Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr. 2006; 1(1):58-65.
    View in: PubMed
    Score: 0.029
  34. Is ethnicity a factor in choice of antihypertensive drug? Postgrad Med. 2005 May; 117(5):40.
    View in: PubMed
    Score: 0.027
  35. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
    View in: PubMed
    Score: 0.027
  36. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6.
    View in: PubMed
    Score: 0.026
  37. Is proteinuria a plausible target of therapy? Curr Hypertens Rep. 2004 Jun; 6(3):177-81.
    View in: PubMed
    Score: 0.026
  38. Hypertension and nephropathy. Am J Med. 2003 Dec 08; 115 Suppl 8A:49S-54S.
    View in: PubMed
    Score: 0.025
  39. Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients? Am J Kidney Dis. 2003 Dec; 42(6):1301-4.
    View in: PubMed
    Score: 0.025
  40. Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Clin Chem. 2023 08 02; 69(8):777-784.
    View in: PubMed
    Score: 0.024
  41. Hypertension in Patients Treated With In-Center Maintenance Hemodialysis: Current Evidence and Future Opportunities: A Scientific Statement From the American Heart Association. Hypertension. 2023 06; 80(6):e112-e122.
    View in: PubMed
    Score: 0.024
  42. Treatment of hypertension in patients with renal disease. Cardiovasc Drugs Ther. 2002 Dec; 16(6):503-10.
    View in: PubMed
    Score: 0.023
  43. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics. 2002; 20(1):37-47.
    View in: PubMed
    Score: 0.022
  44. Choices and goals in the treatment of the diabetic hypertensive patient. Curr Hypertens Rep. 2001 Oct; 3(5):387-91.
    View in: PubMed
    Score: 0.021
  45. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 11; 72(5):e53-e90.
    View in: PubMed
    Score: 0.017
  46. Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. J Am Heart Assoc. 2018 10 16; 7(20):e009114.
    View in: PubMed
    Score: 0.017
  47. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. Am J Cardiol. 2018 11 01; 122(9):1496-1505.
    View in: PubMed
    Score: 0.017
  48. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018 Apr 03; 319(13):1319-1320.
    View in: PubMed
    Score: 0.017
  49. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018 06; 71(6):851-865.
    View in: PubMed
    Score: 0.017
  50. High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017 Oct; 192:76-84.
    View in: PubMed
    Score: 0.016
  51. Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. J Clin Hypertens (Greenwich). 2017 Jul; 19(7):695-701.
    View in: PubMed
    Score: 0.016
  52. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016 07; 2(3):200-5.
    View in: PubMed
    Score: 0.015
  53. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
    View in: PubMed
    Score: 0.015
  54. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004.
    View in: PubMed
    Score: 0.014
  55. Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. J Am Soc Hypertens. 2015 Apr; 9(4):299-306.
    View in: PubMed
    Score: 0.013
  56. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014 Jan; 32(1):3-15.
    View in: PubMed
    Score: 0.012
  57. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014 Jan; 16(1):14-26.
    View in: PubMed
    Score: 0.012
  58. Rationale for establishing a mechanism to increase reimbursement to hypertension specialists. J Clin Hypertens (Greenwich). 2013 Jun; 15(6):397-403.
    View in: PubMed
    Score: 0.012
  59. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013 May; 8(5):731-8.
    View in: PubMed
    Score: 0.012
  60. Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med. 2012 Jul; 125(7):661-9.
    View in: PubMed
    Score: 0.011
  61. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012 Jan 09; 172(1):41-7.
    View in: PubMed
    Score: 0.011
  62. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
    View in: PubMed
    Score: 0.011
  63. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011 May 17; 57(20):2037-114.
    View in: PubMed
    Score: 0.010
  64. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 May 31; 123(21):2434-506.
    View in: PubMed
    Score: 0.010
  65. National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2010: executive summary. Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S1-3.
    View in: PubMed
    Score: 0.010
  66. Sustainable community-based CKD screening methods employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S4-8.
    View in: PubMed
    Score: 0.010
  67. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Catheter Cardiovasc Interv. 2010 Aug 01; 76(2):E43-86.
    View in: PubMed
    Score: 0.010
  68. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010 Jul 07; 304(1):61-8.
    View in: PubMed
    Score: 0.010
  69. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine. J Am Coll Cardiol. 2010 Apr 06; 55(14):e27-e129.
    View in: PubMed
    Score: 0.010
  70. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010 Apr 06; 121(13):e266-369.
    View in: PubMed
    Score: 0.010
  71. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S23-33.
    View in: PubMed
    Score: 0.010
  72. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010 Mar; 3(2):253-60.
    View in: PubMed
    Score: 0.009
  73. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21.
    View in: PubMed
    Score: 0.009
  74. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension. 2008 Jul; 52(1):30-6.
    View in: PubMed
    Score: 0.008
  75. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S46-55.
    View in: PubMed
    Score: 0.008
  76. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press. 2008; 17(1):7-17.
    View in: PubMed
    Score: 0.008
  77. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr. 2008; 3(4):211-7.
    View in: PubMed
    Score: 0.008
  78. Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42.
    View in: PubMed
    Score: 0.008
  79. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007 Jun 11; 167(11):1122-9.
    View in: PubMed
    Score: 0.008
  80. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007 Jan; 30(1):162-72.
    View in: PubMed
    Score: 0.008
  81. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16(1):13-9.
    View in: PubMed
    Score: 0.008
  82. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007 Jan 02; 115(1):114-26.
    View in: PubMed
    Score: 0.008
  83. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):840-9.
    View in: PubMed
    Score: 0.008
  84. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
    View in: PubMed
    Score: 0.007
  85. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005 Nov; 28(11):2686-90.
    View in: PubMed
    Score: 0.007
  86. Association of NEDD4L ubiquitin ligase with essential hypertension. Hypertension. 2005 Sep; 46(3):488-91.
    View in: PubMed
    Score: 0.007
  87. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005 Apr; 67(4):1483-8.
    View in: PubMed
    Score: 0.007
  88. Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J. 2004 Aug; 148(2):243-51.
    View in: PubMed
    Score: 0.006
  89. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003 Oct; 42(4):617-22.
    View in: PubMed
    Score: 0.006
  90. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
    View in: PubMed
    Score: 0.006
  91. The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S166-72.
    View in: PubMed
    Score: 0.006
  92. Barriers to blood pressure control in African Americans. Overcoming obstacles is challenging, but target goals can be attained. Postgrad Med. 2002 Oct; 112(4):51-2, 55, 59-62 passim.
    View in: PubMed
    Score: 0.006
  93. Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome. Postgrad Med. 2002 Oct; 112(4):24-6, 29-30, 33-4 passim.
    View in: PubMed
    Score: 0.006
  94. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000 Feb 28; 160(4):481-90.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.